









市場行情
/
股票
/
nasdaq-exas
/

Exact Sciences Corp

EXAS

101.560USD

-0.340-0.33%

收盤 12/31, 16:00（美東）報價延遲15分鐘

19.24B總市值

虧損本益比TTM



Exact Sciences Corp

101.560

-0.340-0.33%

概覽公司財務分析

概覽

公司

財務

分析

關於 Exact Sciences Corp 公司

Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Exact Sciences Corp簡介



公司代碼EXAS

公司名稱Exact Sciences Corp

上市日期Jan 30, 2001

CEOConroy (Kevin T)

員工數量6900

證券類型Ordinary Share

年結日Jan 30

公司地址5505 Endeavor Lane

城市MADISON

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編53719

電話16082845700

網址https://www.exactsciences.com/

公司代碼EXAS

上市日期Jan 30, 2001

CEOConroy (Kevin T)

Exact Sciences Corp公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Kevin T. Conroy

Chairman of the Board, President, Chief Executive Officer

1.14M

-20.54%

Ms. Katherine S. (Kay) Zanotti

Independent Director

60.76K

-16.49%

Mr. Daniel J. (Dan) Levangie

Independent Director

34.31K

+18.67%

Ms. Shacey Petrovic

Independent Director

28.90K

+22.97%

Mr. Brian Baranick

Executive Vice President, General Manager - Precision Oncology

23.04K

-11.04%

Ms. Leslie L. Trigg

Independent Director

17.17K

+80.75%

Ms. Kimberly J. (Kim) Popovits

Independent Director

16.38K

+156.47%

Mr. Aaron Bloomer

Chief Financial Officer, Executive Vice President

13.84K

Mr. Michael J. (Mike) Barber, M.D.

Independent Director

13.14K

+121.18%

Mr. James E. Doyle

Lead Independent Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Kevin T. Conroy

Chairman of the Board, President, Chief Executive Officer

1.14M

-20.54%

Ms. Katherine S. (Kay) Zanotti

Independent Director

60.76K

-16.49%

Mr. Daniel J. (Dan) Levangie

Independent Director

34.31K

+18.67%

Ms. Shacey Petrovic

Independent Director

28.90K

+22.97%

Mr. Brian Baranick

Executive Vice President, General Manager - Precision Oncology

23.04K

-11.04%

Ms. Leslie L. Trigg

Independent Director

17.17K

+80.75%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

Commercial

387.50M

47.78%

Medicare Parts B & C

274.49M

33.84%

Other

93.84M

11.57%

International

55.26M

6.81%

地區USD

名稱

營收

佔比

United States (Country)

755.83M

93.19%

Outside of united states

55.26M

6.81%

業務

地區

業務USD

名稱

營收

佔比

Commercial

387.50M

47.78%

Medicare Parts B & C

274.49M

33.84%

Other

93.84M

11.57%

International

55.26M

6.81%

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

9.36%

Capital World Investors

8.51%

Fidelity Management & Research Company LLC

8.11%

BlackRock Institutional Trust Company, N.A.

3.77%

Wellington Management Company, LLP

2.81%

其他

67.45%

持股股東

佔比

The Vanguard Group, Inc.

9.36%

Capital World Investors

8.51%

Fidelity Management & Research Company LLC

8.11%

BlackRock Institutional Trust Company, N.A.

3.77%

Wellington Management Company, LLP

2.81%

其他

67.45%

股東類型

持股股東

佔比

Investment Advisor

51.08%

Investment Advisor/Hedge Fund

27.76%

Hedge Fund

9.78%

Pension Fund

2.26%

Research Firm

2.00%

Individual Investor

0.91%

Private Equity

0.77%

Bank and Trust

0.59%

Sovereign Wealth Fund

0.48%

其他

4.37%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

1336

180.61M

95.18%

-13.94M

2025Q3

1352

180.95M

106.13%

-112.86K

2025Q2

1416

180.92M

107.16%

-6.42M

2025Q1

1400

186.11M

105.23%

-12.34M

2024Q4

1391

186.68M

107.44%

-1.15M

2024Q3

1351

188.95M

104.99%

+4.63M

2024Q2

1335

183.23M

95.81%

+15.73M

2024Q1

1330

166.64M

95.05%

-5.91M

2023Q4

1339

163.38M

96.52%

-2.83M

2023Q3

1319

166.02M

95.28%

+1.45M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

17.76M

9.36%

-101.97K

-0.57%

Sep 30, 2025

Capital World Investors

16.14M

8.51%

-2.06M

-11.31%

Sep 30, 2025

Fidelity Management & Research Company LLC

15.38M

8.11%

-7.90M

-33.94%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

7.15M

3.77%

+116.86K

+1.66%

Sep 30, 2025

Wellington Management Company, LLP

5.33M

2.81%

-6.68M

-55.63%

Sep 30, 2025

State Street Investment Management (US)

5.20M

2.74%

-183.75K

-3.42%

Sep 30, 2025

Citadel Advisors LLC

3.94M

2.08%

+3.51M

+805.07%

Sep 30, 2025

MFS Investment Management

3.82M

2.01%

+855.10K

+28.85%

Sep 30, 2025

Columbia Threadneedle Investments (US)

3.73M

1.96%

+3.35M

+899.61%

Sep 30, 2025

Geode Capital Management, L.L.C.

3.31M

1.75%

+74.79K

+2.31%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

First Trust Nasdaq Lux Digi Health Solutions ETF

4.48%

Invesco Biotechnology & Genome ETF

3.72%

First Trust NYSE Arca Biotechnology Index Fund

3.72%

Alger Mid Cap 40 ETF

3.61%

Clough Select Equity ETF

3.13%

Clough Hedged Equity ETF

2.78%

iShares Health Innovation Active ETF

2.72%

State Street SPDR S&P Biotech ETF

2.32%

First Trust Indxx Medical Devices ETF

2.22%

ROBO Global Healthcare Technology & Innovation ETF

2.03%

First Trust Nasdaq Lux Digi Health Solutions ETF

佔比4.48%

Invesco Biotechnology & Genome ETF

佔比3.72%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.72%

Alger Mid Cap 40 ETF

佔比3.61%

Clough Select Equity ETF

佔比3.13%

Clough Hedged Equity ETF

佔比2.78%

iShares Health Innovation Active ETF

佔比2.72%

State Street SPDR S&P Biotech ETF

佔比2.32%

First Trust Indxx Medical Devices ETF

佔比2.22%

ROBO Global Healthcare Technology & Innovation ETF

佔比2.03%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Exact Sciences Corp的前五大股東是誰？



Exact Sciences Corp的前五大股東如下：
The Vanguard Group, Inc.
持有股份：17.76M
佔總股份比例：9.36%。
Capital World Investors
持有股份：16.14M
佔總股份比例：8.51%。
Fidelity Management & Research Company LLC
持有股份：15.38M
佔總股份比例：8.11%。
BlackRock Institutional Trust Company, N.A.
持有股份：7.15M
佔總股份比例：3.77%。
Wellington Management Company, LLP
持有股份：5.33M
佔總股份比例：2.81%。